Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

By Chapple C   DuBeau C   Ebinger U   Rekeda L   Viegas A  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2347-2358

Informa Healthcare

Access to resources Recommend Favorite

A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis

By Finn William F.   Joy Melanie S.    

Current Medical Research and Opinion, Vol. 21, Iss. 5, 2005-05 ,pp. : 657-664

Informa Healthcare

Access to resources Recommend Favorite

Analysis of Integrated Radiographic Data From Two Long‐Term, Open‐Label Extension Studies of Adalimumab for the Treatment of Rheumatoid Arthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 2, 2015-02 ,pp. : 180-186

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study

By Herschorn S.   Pommerville P.   Stothers L.   Egerdie B.   Gajewski J.   Carlson K.   Radomski S.   Drutz H.   Schulz J.   Barkin J.   Hirshberg E.   Corcos J.  

Current Medical Research and Opinion, Vol. 27, Iss. 2, 2011-02 ,pp. : 375-382

Informa Healthcare

Access to resources Recommend Favorite

Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study*

By Philipp Thomas   Glazer Robert D.   Zhao Yanxing   Pospiech Rainer  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 187-193

Informa Healthcare

Access to resources Recommend Favorite